Results 31 to 40 of about 21,053 (285)

Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model. [PDF]

PLoS ONE, 2018
Increasing use of factor Xa (FXa) inhibitors necessitates effective reversal agents to manage bleeding. Andexanet alfa, a novel modified recombinant human FXa, rapidly reverses the anticoagulation effects of direct and indirect FXa inhibitors.To evaluate
Genmin Lu, Polly Pine, Janet M Leeds, Francis DeGuzman, Pratikhya Pratikhya, Joyce Lin, John Malinowski, Stanley J Hollenbach, John T Curnutte, Pamela B Conley   +9 more
doaj   +1 more source

Edoxaban dosing patterns in real life practice – Results from the DRESDEN NOAC REGISTRY

Thrombosis Update, 2021
Edoxaban is a non-vitamin K dependent oral anticoagulant (NOAC) licensed for venous thromboembolism treatment or stroke prevention in atrial fibrillation.
Jan Beyer-Westendorf, Sandra Marten, Christiane Naue, Christina Köhler, Luise Tittl, Martin Bornhäuser   +5 more
doaj   +1 more source

Edoxaban Dosing Time Affects Blood Coagulation Inhibition in Rats

TH Open, 2021
Coagulation–fibrinolytic system activity shows daily rhythmicity, with hypercoagulability in the morning and hypocoagulability in the evening. Consequently, the efficacy of anticoagulants may be influenced by their dosing time.
Naoto Nagata, Muneo Kawasumi, Akio Fujimura, Hitoshi Ando   +3 more
doaj   +1 more source

Edoxaban-induced enterocolitis: The first case report demonstrating distinct endoscopic and histological features. [PDF]

DEN Open
Abstract Direct oral anticoagulants (DOACs), including edoxaban, are widely used for stroke prevention in atrial fibrillation and venous thromboembolism. While gastrointestinal bleeding and diarrhea are recognized adverse effects, DOAC‐induced enterocolitis has not been established as a distinct clinical entity.
Endo K, Yamada J, Katayama T, Yoshino Y, Fukushi D, Koiwai A, Kogure T, Hirota M, Satoh K.   +8 more
europepmc   +2 more sources

Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR.

New England Journal of Medicine, 2021
BACKGROUND The role of direct oral anticoagulants as compared with vitamin K antagonists for atrial fibrillation after successful transcatheter aortic-valve replacement (TAVR) has not been well studied.
N. V. Van Mieghem, M. Unverdorben, C. Hengstenberg, H. Möllmann, R. Mehran, D. Lopez-Otero, L. Nombela‐Franco, R. Moreno, P. Nordbeck, H. Thiele, I. Lang, J. Zamorano, F. Shawl, M. Yamamoto, Y. Watanabe, K. Hayashida, R. Hambrecht, F. Meincke, P. Vranckx, James Jin, E. Boersma, J. Rodés‐Cabau, P. Ohlmann, P. Capranzano, Hyo‐Soo Kim, T. Pilgrim, Richard Anderson, U. Baber, A. Duggal, P. Laeis, H. Lanz, Cathy Chen, M. Valgimigli, R. Veltkamp, S. Saito, G. Dangas   +35 more
semanticscholar   +1 more source

The edoxaban‐M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma

Research and Practice in Thrombosis and Haemostasis, 2022
Introduction Edoxaban is the only anti‐Xa inhibitor metabolized in pharmacologically active moiety that could interfere with chromogenic anti‐Xa assays, especially in case of drug‐drug interactions or physiological disorders.
Romain Siriez, Halil Yildiz, Céline Bouvy, Hélène Haguet, Vincent Maloteau, Michaël Hardy, François Mullier, Jean‐Michel Dogné, Philippe Hainaut, Jonathan Douxfils   +9 more
doaj   +1 more source

Edoxaban [PDF]

Reactions Weekly, 2021
Kirsten Mitchell, Andrea Llano
  +8 more sources

Effects of concomitant use of prasugrel with edoxaban on bleeding time, pharmacodynamics, and pharmacokinetics of edoxaban in healthy elderly Japanese male subjects: a clinical pharmacology study

Thrombosis Journal, 2020
Background Dual therapy with a direct oral anticoagulant (DOAC) plus a P2Y12 receptor inhibitor is recommended in patients with nonvalvular atrial fibrillation who undergo percutaneous coronary intervention.
Ippei Ikushima, Takaaki Akasaka, Yoshiyuki Morishima, Atsushi Takita, Tomoko Motohashi, Tetsuya Kimura   +5 more
doaj   +1 more source

Anticoagulation with edoxaban in patients with long atrial high-rate episodes ≥24 h

European Heart Journal, 2023
Background and Aims Patients with long atrial high-rate episodes (AHREs) ≥24 h and stroke risk factors are often treated with anticoagulation for stroke prevention.
N. Becher, Tobias Toennis, E. Bertaglia, Carina Blomström-Lundqvist, A. Brandes, N. Cabanelas, Melanie Calvert, A. Camm, G. Chlouverakis, G. Dan, W. Dichtl, Hans-Christoph Diener, Alexander Fierenz, A. Goette, J. D. de Groot, A. Hermans, Gregory Y.H Lip, Andrzej Lubinski, E. Marijon, B. Merkely, Lluís Mont, A. Ozga, K. Rajappan, A. Sarkozy, Daniel Scherr, Renate B Schnabel, U. Schotten, S. Sehner, E. Simantirakis, P. Vardas, V. Velchev, D. Wichterle, A. Zapf, P. Kirchhof   +33 more
semanticscholar   +1 more source

Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants including edoxaban

Neurological Research and Practice, 2021
Background Direct oral anticoagulants (DOAC) including edoxaban are increasingly used for stroke prevention in atrial fibrillation. Despite treatment, annual stroke rate in these patients remains 1–2%.
Florian Härtig, Ingvild Birschmann, Andreas Peter, Sebastian Hörber, Matthias Ebner, Matthias Sonnleitner, Charlotte Spencer, Paula Bombach, Maria-Ioanna Stefanou, Johannes Tünnerhoff, Annerose Mengel, Joachim Kuhn, Ulf Ziemann, Sven Poli   +13 more
doaj   +1 more source